secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2026-01-23T23:59:59+00:00
Accession:  0001493152-26-003445
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma CFO Keith Kucinski resigns; CEO Jerome Jabbour named interim CFO
--------------------------------------------------------------------------------

- Keith Kucinski resigned as CFO effective January 17, 2026, to pursue other opportunities.
- Board appointed CEO and Chairman Jerome D. Jabbour as interim CFO effective January 22, 2026.
- Jabbour retains roles as Chairman, President, and CEO; assumes principal financial and accounting officer duties.
- No change in Jabbour's compensation or other material terms in connection with appointment.
- No family relationships or transactions between Jabbour and any director or officer requiring disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315226003445/0001493152-26-003445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315226003445/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-003445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer